Search

everythinglearnresearchcommunity

for

Search:↓

Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Alopecia areata causes significant financial strain and dissatisfaction with treatment in Norway and Sweden.

Alopecia areata in Taiwan has a high disease burden and needs better research and diagnostic criteria.

Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.

Individualized treatment and psychological support improved the patient's quality of life and appearance despite medication side effects.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

Non-scarring hair loss in lupus patients often responds well to treatment and doesn't lead to scarring.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.

Alopecia is common in lupus patients, causing significant anxiety and is linked to the disease itself.

Alopecia areata is a common autoimmune condition causing varying hair loss, diagnosed by specific patterns of inflammation around hair follicles, with several treatment options available.

Low-dose oral and sublingual minoxidil seem safe for children with hair disorders.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

Clobetasol propionate ointment can help some people with total hair loss regrow hair.

No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.

The paper concludes that the 1982 criteria for diagnosing systemic lupus erythematosus need updating to improve accuracy and involve dermatologists in the process.

Tph cells are linked to the severity of systemic lupus erythematosus.

There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.

The document suggests a personalized treatment plan for alopecia areata based on the patient's age and hair loss severity, using a range of therapies ranked by effectiveness and safety.

The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.

Sulfasalazine may help regrow hair in severe alopecia areata cases.

Different treatments for alopecia areata have varying success rates and side effects; intralesional steroids are most effective.

Contact sensitizers like DCP and SADBE are the most effective treatments for alopecia areata.

Some treatments can help with hair regrowth in alopecia areata, but results vary and long-term use is often needed without changing the disease's outcome.

Some treatments like intralesional steroids and 5α-reductase inhibitors are effective for frontal fibrosing alopecia, but more research is needed.

People with alopecia areata often have lower vitamin D levels and more inflammation, suggesting vitamin D might be involved in the condition.

Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.